Search clinical trials for: Radio Immunotherapy

Total 21169 results

Cedars-Sinai Medical Center
AstraZeneca

Withdrawn

Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer (PANDoRA)

Breast Cancer | Triple Negative Breast Cancer

United States
Weill Medical College of Cornell University

Terminated

Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M) (RISE-M)

Multiple Myeloma

United States
University of Chicago

Terminated

Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer

Hepatocellular Carcinoma

United States
Andrew Sharabi
Pfizer

Terminated

Stereotactic Body Radiation Therapy (SBRT) Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)

Early Stage Non-Small Cell Lung Cancer

United States
Linda R Duska
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer

Cervical Cancer

United States
Tongji Hospital
Wuhan University; Sun Yat-sen University; Wuhan Union Hospital, China

Suspended

Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
SOTIO a.s.

Completed

Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer (VIABLE)

Metastatic Castration-resistant Prostate Cancer

United States, Spain, United Kingdom, Germany, Serbia, Portugal, Lithuania, Slovakia, Hungary, Netherlands, Croatia, France, Czechia, Poland, Austria, Belarus, Belgium, Bulgaria, Denmark, Italy, Latvia, Sweden
Oslo University Hospital

Terminated

Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC (COM-IT-1)

Non-small Cell Lung Cancer

Norway
ImmunityBio, Inc.

Withdrawn

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Melanoma
ImmunityBio, Inc.

Withdrawn

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Head and Neck Squamous Cell Carcinoma
ImmunityBio, Inc.

Withdrawn

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Merkel Cell Carcinoma
ImmunityBio, Inc.

Withdrawn

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Non-small Cell Lung Cancer
ImmunityBio, Inc.

Withdrawn

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Triple Negative Breast Cancer
ImmunityBio, Inc.

Withdrawn

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Colorectal Cancer
ImmunityBio, Inc.

Withdrawn

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Ovarian Cancer
ImmunityBio, Inc.

Withdrawn

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Non Hodgkin Lymphoma
ImmunityBio, Inc.

Withdrawn

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Urothelial Carcinoma
Oslo University Hospital
Merck Sharp & Dohme LLC; Norwegian Cancer Society

Completed

Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma (Lymvac-2)

Follicular Lymphoma

Norway
Lund University Hospital

Unknown

Haploidentical Stem Cell Transplantation in Neuroblastoma

Neuroblastoma

Sweden
Taipei Medical University WanFang Hospital

Completed

Immune Profile and Prognosis of Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy (RFA)

Liver Cancer

Taiwan
James Larner, MD

Completed

HDCRT Plus Pembrolizumab in Advanced Malignancies (UVA-AM-001)

Solid Tumor

United States
United Therapeutics

Completed

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

United States, Canada, Spain, Australia, Korea, Republic of, France, United Kingdom, Thailand, Malaysia, Hungary, Poland, Taiwan, Philippines, Hong Kong, Lithuania, Georgia, Bulgaria, India, Italy, Romania, Russian Federation, Slo... and more
Wuhan Union Hospital, China

Active, not recruiting

Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer

Rectal Cancer | Radiotherapy | Immunotherapy

China
Washington University School of Medicine
Merck Sharp & Dohme LLC

Completed

MK-3475 Immunotherapy in Endometrial Carcinoma

Endometrial Cancer | Endometrial Carcinoma | Neoplasms, Endometrial

United States
Oxford BioMedica
Sanofi

Completed

TroVax Renal Immunotherapy Survival Trial

Clear Cell Renal Carcinoma

United States, Spain, Israel, United Kingdom, France, Russian Federation, Germany, Poland, Romania, Ukraine
Huashan Hospital
Fudan University

Unknown

Study of DC Vaccination Against Glioblastoma

Glioma | Neoplasms | Glioblastoma Multiforme

China
Gary Onik MD

Completed

A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen. (NIRPA)

Adenocarcinoma

United States
CSL Behring

Completed

Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia

Fatigue | NSCLC | Cachexia

Canada, Australia, Russian Federation, Georgia, Serbia, India, New Zealand, Poland, Romania
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangdong Provincial People's Hospital

Unknown

CT-based Radiomic Algorithm for Assisting Surgery Decision and Predicting Immunotherapy Response of NSCLC (TOP-RLC)

Lung Cancer | Predictive Cancer Model | Preinvasive Adenocarcinoma

China
Sun Yat-sen University

Active, not recruiting

Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer (ACCORD)

Biliary Tract Cancer | Gallbladder Cancer | Extrahepatic Cholangiocarcinoma

China
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis (COAST-W)

Spondyloarthritis

Italy, Japan, United States, Puerto Rico, Spain, Mexico, Netherlands, France, Poland, Israel, Argentina, Brazil, Canada, Korea, Republic of, Germany, Finland, United Kingdom
H. Lee Moffitt Cancer Center and Research Institute
National Comprehensive Cancer Network

Withdrawn

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

Liver Cancer | HepatoCellular Carcinoma | Unresectable HepatoCellular Carcinoma

United States
Fudan University

Unknown

The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

China
Fudan University

Unknown

The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

China
NewLink Genetics Corporation

Completed

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Pancreatic Cancer

United States
NYU Langone Health
Bristol-Myers Squibb

Completed

Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)

United States
CytoVac A/S

Completed

Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma (ALECSAT)

Glioblastoma

Sweden
Massachusetts General Hospital

Completed

A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy

Melanoma | Glioblastoma | Intracranial Tumors

United States
Case Comprehensive Cancer Center

Withdrawn

Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer

Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and...
Sun Yat-sen University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaborators

Completed

Radiomics of Immunotherapeutics Response Evaluation and Prediction (RIREP)

Solid Tumor | Predictive Cancer Model

China
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis (COAST-X)

Axial Spondyloarthritis

United States, Puerto Rico, Russian Federation, Mexico, Poland, Argentina, Austria, Brazil, Canada, Czechia, Finland, Germany, Japan, Korea, Republic of, Netherlands, Romania
The Netherlands Cancer Institute
AstraZeneca

Unknown

Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment (Induction)

Stage III NSCLC

Netherlands
Clinica Universidad de Navarra, Universidad de...

Completed

Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults (DEND/TIA)

Sarcoma | Central Nervous System Tumor

Spain
Guangxi Medical University

Unknown

RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC)

Hepatocellular Carcinoma
Philip Schaner
National Cancer Institute (NCI)

Terminated

EPR Tumor Oximetry With CE India Ink

Melanoma | Head and Neck Neoplasms | Carcinoma, Squamous Cell | Carcinoma, Basal Cell | Breast Neoplasm | Neoplasms, Malignant | Skin Neoplasm

United States
University Hospital Regensburg

Completed

Psychometric Properties of the EORTC QLQ-LC29

Lung Cancer

Germany
National Cancer Institute (NCI)

Completed

Tremelimumab With Chemoembolization or Ablation for Liver Cancer

Hepatocellular Carcinoma | Biliary Tract Neoplasms | Liver Cancer | Biliary Cancer | Heptocellular Cancer

United States
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis (COAST-V)

Spondyloarthritis

Taiwan, United States, Korea, Republic of, Germany, Czechia, Japan, Netherlands
Capital Medical University

Unknown

Adoptive Cellular Therapy and Radiation Therapy After Surgery in Treating Patients With Esophageal Cancer

Esophageal Cancer

China
University of Colorado, Denver
AstraZeneca

Withdrawn

Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases

Colorectal Cancer

Search clinical trials for: Radio Immunotherapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations